Latest Breaking News On - Aquavit pharmaceuticals inc - Page 3 : vimarsana.com

Aquavit s AQV-1122 COVID-19 Vaccine Patent Approval Fast Tracked by USPTO

Aquavit s AQV-1122 COVID-19 Vaccine Patent Approval Fast Tracked by USPTO
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Sobin changExamination pilot programAquavit pharmaceuticals incPrnewswire aquavit pharmaceuticals incTrack prioritized examination pilot programChief executive officerAntigen presenting cellsLangerhans cellsSai sankarChief biomedical engineerAquavit pharmaceuticals

Aquavit s AQV-1122 COVID-19 Vaccine Patent Approval Fast Tracked by USPTO

Patent Granted to Aquavit for Novel RoA and MoA for Bioactive Compositions

Patent Granted to Aquavit for Novel RoA and MoA for Bioactive Compositions News provided by Share this article Share this article NEW YORK, May 4, 2021 /PRNewswire/ U.S. patent number 10,980,865 [Application Number 14/909,954] was granted to Aquavit Pharmaceuticals, Inc. for direct application system and method for the delivery of bioactive compositions and formulations. The invention utilizes a repeated motion delivery technology (AQT Technology), creating a new route of administration (RoA) and mode of administration (MoA) for the pharmaceutical and biotechnology industry for the first time in decades. “This patent combined with our recent acquisition of a License for a new botulinum toxin asset will ignite many advancements in the industry and provide limitless opportunities for New Drug Applications (NDA) or Biologics License Applications (BLA).” says Sobin Chang, MPH., CEO of Aquavit.

Sobin changDavid shaferAquavit pharmaceuticals incTechnology officerNew drug applicationsBiologics license applicationsChief medical technologySai sankarChief biomedicalAquavit pharmaceuticalsடேவிட் ஷாபெர்தொழில்நுட்பம் அதிகாரிபுதியது மருந்து பயன்பாடுகள்உயிரியல் உரிமம் பயன்பாடுகள்சாய் சங்கர்தலைமை உயிர் மருத்துவ

European Union Intellectual Property Office Revokes Counterfeiter s Fake AQUAGOLD® Design Registrati

Search jobs 10-Dec-2020 European Union Intellectual Property Office Revokes Counterfeiter s Fake AQUAGOLD® Design Registration and Orders Payment to Aquavit of All Legal Fees and Costs NEW YORK, Dec. 10, 2020 /PRNewswire/ Aquavit Pharmaceuticals, Inc. ( Aquavit ) received a decision from the European Union Intellectual Property Office (EUIPO) today that it has revoked the counterfeiter U-BioMed s falsely registered AQUAGOLD® design, originally created and owned by Aquavit. AQUAGOLD® fine touch™ is Aquavit s world-renowned microchannel microinjector medical device. Aquavit introduced AQUAGOLD® fine touch™ at the American Academy of Dermatology (AAD) in 2014 and has been praised globally by doctors, patients, key opinion leaders, and the media. AAD is the largest dermatology conference in the world, attended by tens of thousands of doctors and healthcare professionals from around the world.

New yorkUnited statesSouth koreaSobin changAquavit pharmaceuticals incAmerican academy of dermatologyEuropean union intellectual property officeEuropean unionPrnewswire aquavit pharmaceuticals incUnited states district courtAmerican academyRegistered communityTemporary restraining orderPreliminary injunctionSouthern districtEum nyun

European Union Intellectual Property Office Revokes Counterfeiter s Fake AQUAGOLD® Design Registration and Orders Payment to Aquavit of All Legal Fees and Costs

European Union Intellectual Property Office Revokes Counterfeiter s Fake AQUAGOLD® Design Registration and Orders Payment to Aquavit of All Legal Fees and Costs News provided by Share this article Share this article NEW YORK, Dec. 10, 2020 /PRNewswire/ Aquavit Pharmaceuticals, Inc. ( Aquavit ) received a decision from the European Union Intellectual Property Office (EUIPO) today that it has revoked the counterfeiter U-BioMed s falsely registered AQUAGOLD® design, originally created and owned by Aquavit. (PRNewsfoto/Aquavit Pharmaceuticals, Inc.) fine touch™ is Aquavit s world-renowned microchannel microinjector medical device. Aquavit introduced AQUAGOLD® fine touch™ at the American Academy of Dermatology (AAD) in 2014 and has been praised globally by doctors, patients, key opinion leaders, and the media. AAD is the largest dermatology conference in the world, attended by tens of thousands of doctors and healthcare professionals from around the world.

New yorkUnited statesSouth koreaSobin changAquavit pharmaceuticals incEuropean unionUnited states district courtRegistered communityTemporary restraining orderPreliminary injunctionSouthern districtEum nyunCorea eumChief executiveAquavit pharmaceuticalsபுதியது யார்க்